Drugs / RDEA806
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00741442 | Jul 2008 → Apr 2009 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00617526 | Jan → Jun 2008 | HIV infectious disease | Ardea Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RDEA806 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00617526 ↗ |
| Action | Inhibit | “RDEA806 is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent in vitro activity against wild-type and NNRTI-resistant HIV-1.” PMID 20498326 ↗ May 2010 |